Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)

Rheumatology International

Volumn 27, Issue 5, 2007, Pages 425-434

  Ringe, J D ^a   Farahmand, P ^a   Schacht, E ^b   Rozehnal, A ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b ZORG   (Switzerland)

^c idv Data Analysis and Study Planning   (Germany)

Author keywords

Alendronate; Alfacalcidol; Male osteoporosis; Postmenopausal osteoporosis; Vitamin D

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; CALCIUM; VITAMIN D;

ABSORPTIOMETRY; ADULT; AGED; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; FEMUR; FOLLOW UP; HEADACHE; HEARTBURN; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; METEORISM; NAUSEA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; X RAY;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES; TREATMENT OUTCOME; VITAMIN D;

EID: 33847138963     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-006-0288-z     Document Type: Article

References (55)

1. Gambacciani M, Spinetti A, Cappagli B, Ciaponi M, Gallo R, Rovati LC, Genazzani AR (1995) Effects of low-dose monofluorophosphate and transdermal oestradiol on postmenopausal vertebral bone loss. Eur Menopause J 2:16-20
2. Alexandersen P, Riis BJ, Christiansen C (1999) Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocriol Metab 84:3013-3020
3. Ringe JD, Setnikar I (2002) Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study. Rheumatol Int 22:27-32
4. Lems WF, Jacobs JWG, Bijlsma WJ, van Veen GJM, Houben HHML, Haanen HCM, Gerrits MI, van Rijn HJM (1997) Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticoid induced osteoporosis? Ann Rheumatol Dis 56:357-363
5. Ringe JD, Rovati L (2001) Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 69:252-255
6. Morabito N, Gaudio A, Lasco A, Vergara C, Tallarida F, Crisafulli G, Trifiletti A, Cincotta M, Pizzoleo MA, Frisina N (2003) Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. Osteoporos Int 14:500-506
7. Ringe JD, Dorst A, Faber H, Kipshoven C, Rovati LC, Setnikar I (2005) Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study. Rheumatol Int 25:296-300
8. Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T (2003) Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int 14:741-749
9. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH (1995) The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate. Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610
10. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
11. Ringe JD, Schacht E (2004) Prevention and therapy of osteoporosis: the roles of plain Vitamin D and alfacalcidol. Rheumatol Int 24:189-197
12. Fujita T, Fukase M, Shimada T, Yamamoto H (1992) Treatment of established osteoporosis with 1α-(OH)-Vitamin D3 and low dose intermittent Elcalcitonin (eel calcitonin derivative). JBBM 10:37-40
13. Ushiroyama T, Ikeda A, Sakai M, Higashiyama T, Ueki M (2001) Effects of combined use of calcitonin and 1α-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin. Maturitas 40:229-238
14. Frediani B, Allegri A, Bisogno S, Marcolongo R (1998) Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis. Two years of continuous treatment. Clin Drug Invest 15(3):235-244
15. Ringe JD (2006) Alfacalcidol in prevention and treatment of all major forms of osteoporosis and renal osteopathy. Georg Thieme Verlag, Stuttgart
16. Schacht E, Richy F, Reginster JY (2005) The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact 5(3):273-284
17. Fligner MA, Wolfe DA (1982) Distribution-free tests for comparing several treatments with a control. Stat Neerl 36:119-127
18. Lachin JM (1992) Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Stat Med 11:1151-1170
19. Thall PF, Lachin JM (1988) Analysis of recurrent events: nonparametric methods for random interval count data. J Am Stat Assoc 83:339-347
20. Wei LJ, Lachin JM (1984) Two-sample asymptotically distribution-free tests for incomplete multivariate observations. J Am Stat Assoc 79:653-661
21. Colditz GA, Miller JN, Mosteller F (1988) Measuring gain in the evaluation of medical technology: the probability of a better outcome. Int J Technol Assessment Health Care 4:637-642
22. 3 on bone loss by ovariectomy in aged rats. Jpn J Pharmacol 89:255-266
23. 3. J Bone Miner Res 17:1498-1511
24. 2 vitamin D3 are detected only in the presence of a powerful antiresorptive. J Bone Miner Res 19(Suppl 1):S483
25. Ikeda K, Ogata E (1999) The effect of vitamin D on osteoblasts and osteoclasts. Curr Opin Orthop 10:339-343
26. Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11:192-202
27. Youm T, Koval KJ, Kummer FJ, Zuckerman JD (1999) Do all hip fractures result from a fall? Am J Orthop 28:190-194
28. Kaptoge S, Benevolenskaya LI, Bhalla AK, Cannata JB, Boonen S, Falch JA et al (2005) Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. Bone 36:387-398
29. Runge M, Schacht E (2005) Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J Musculoskelet Neuronal Interact 5:127-134
30. Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, Hochberg MC, Vogt MT, Orwoll ES, for the Study of Osteoporotic Fractures Research Group (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90:2787-2793
31. Nevitt MC, Cummings SR, Stone KL, Palermo L, Black DM, Bauer DC et al (2005) Risk factors for a first-incident radiographic vertebral fracture in women ≥ 65 years of age: the study of osteoporotic fractures. J Bone Miner Res 20:131-140
32. Bischoff HA, Borchers M, Gudat F, Duermueller U, Theiler R, Stähelin HB et al (2001) In situ detection of 1,25-dihydroxyvitamin D receptor in human skeletal muscle tissue. Histochem 33:19-24
33. Boland R (1986) Role of vitamin D in skeletal muscle function. Endocrine Rev 784:434-448
34. Endo I, Inoue D, Mitsui T, Umaki Y, Akaike M, Yoshizawa T et al (2003) Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 144:5138-5144
35. Bischoff-Ferrari HA, Borchers M, Gudat F, Dürmüller U, Stähelin HB, Dick W (2004) Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 19:265-269
36. Bischoff HA, Stähelin HB, Urscheler N, Ehrsam R, Vontheim R, Perrig-Chiello P et al (1999) Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 80:54-58
37. Dukas L, Schacht E, Bischoff HA (1999) Better functional mobility in community-dwelling elderly is related to D-hormone serum levels and to a daily calcium intake. J Nutr Health Aging 9:347-351
38. Gallagher JC (2004) The effects of calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Mol Biol 89-90:497-501
39. Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN et al (2004) Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 52:230-236
40. Dukas L, Schacht E, Mazor Z, Stähelin HB (2005) Treatment with Alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of >65 ml/min. Osteoporos Int 16:198-203
41. Uusi-Rasi K, Kannus P, Cheng S et al (2003) Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial. Bone 33:132-143
42. Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80-100
43. Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97-106
44. Shibata T, Shiraishi A, Masaki T, Sasaki A, Masuda Y, Hishiya A, Ishikura N, Higashi S, Uchida Y, Saito M, Ito M, Ogata E, Watanabe K, Ikeda K (2002) Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 17:622-629
45. DeLuca HF, Cantorna MT (2001) Vitamin D. Its role and uses in immunology. FASEB J 15:2579-2585
46. Hayakawa N, Higashi S, Shiraishi A, Masaki T, Hoshino E, Matsubara S (2002) Alfacalcidol distributes to bone marrow cells in an unchanged form and converts to active forms locally. J Bone Min Res 17(Suppl 1):S276
47. Richy F, Ethgen O, Bruyere O, Reginster JY (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301-310
48. Malavolta N, Zanardi M, Veronesi M, Ripamonti C, Gnudi S (1999) Calcitriol and alendronate combination treatment in menopausal women with low bone mass. Int J Tissue React 21:51-59
49. Masud T, Mulcahy B, Thompson AV, Donnelly S, Keen RW, Doyle DV, Spector TD (1998) Effects of cyclical Etidronate combined with calcitriol versus cyclical Etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis 57:346-349
50. Iwamoto J, Takeda T, Ichimura S, Matsu K, Uzawa M (2003) Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis. J Orthop Sci 8:532-537
51. Ones K, Schacht E (2006) Superiority of a combined treatment of Alfacalcidol and Alendronate compared to the monotherapies in postmenopausal osteoporosis. Osteoporos Int 17(1):S20(P112)
52. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, et al (1999) The advantage of Alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int 65:311-316
53. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY et al (2004) Effect of vitamin D on falls. A meta-analysis. JAMA 291:1999-2006
54. Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY (2005) Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 76:176-186
55. 3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365:1621-1628